Orion Pharma Advances TEAD Inhibitor Into Combination Trials

Orion Pharma has initiated the TEADCO Phase 1b/2 basket trial, placing its oral pan-TEAD inhibitor ODM-212 into combination regimens across three treatment-resistant solid tumour indications. For API developers and contract manufacturers tracking emerging oncology pipelines, TEAD/Hippo pathway inhibition is moving from preclinical hypothesis to active clinical evaluation, with combination demand implications for sotorasib, nivolumab, ipilimumab, nab-paclitaxel, and gemcitabine supply chains.

The multi-centre, open-label trial spans three cohorts. The first evaluates ODM-212 with ipilimumab and nivolumab as first-line therapy in advanced malignant pleural mesothelioma, a rare cancer accounting for 80 to 90 percent of all mesothelioma cases and strongly linked to asbestos exposure. The second cohort pairs ODM-212 with sotorasib in KRAS G12C-mutated NSCLC, a mutation present in approximately 13 percent of NSCLC patients, with sub-cohorts stratified by prior KRAS inhibitor exposure. The third cohort combines ODM-212 with nab-paclitaxel and gemcitabine chemotherapy in metastatic pancreatic adenocarcinoma, where treatment options remain limited.

Mechanism and resistance rationale: ODM-212 targets TEAD transcription factors within the Hippo signalling pathway by disrupting YAP-TEAD protein-protein interactions and inhibiting TEAD auto-palmitoylation. Dysregulation of this pathway through YAP/TAZ activation is associated with uncontrolled tumour growth and resistance to existing therapies. Orion positions ODM-212 as having the potential to both exert direct anti-tumour activity and prevent or overcome resistance to approved standard of care treatments across these indications.

Executive perspective: Professor Outi Vaarala, Executive Vice President of Research and Development at Orion, stated: "Together with the ongoing TEADES study, TEADCO highlights the versatility of ODM-212 both as monotherapy and in combination with other treatments. We remain focused on advancing and expanding ODM-212 clinical development program." The TEADES study is referenced as a concurrent monotherapy evaluation, though no further detail on that trial was provided in the announcement.

Source: Orion Corporation press release, 23 April 2026, via GlobeNewswire.